Results 121 to 130 of about 14,530 (214)

uPAR is constitutively internalized in the absence of ligands.

, 2013
In all cases, the images presented are representative of 3–5 independent experiments. Panel A shows a biotinylation assay performed in HT1080 cells.
Francesco Blasi (61418), Carlo Tacchetti (252415), Katia Cortese (166183), Macarena Sahores (375932), Chris D. Madsen (375934)   +4 more
core   +1 more source

uPAR depletion or blocking impairs migration of uPAR-expressing cells.

, 2014
A: Prostate carcinoma (PC3) cells were transfected with a uPAR-targeting siRNA or a non-targeting control siRNA; then, cells were partly lysed for Western blot analysis with a uPAR-specific antibody (left) and partly loaded in Boyden chamber and allowed ...
Nunzia Montuori (511913), Giuseppina Amodio (511911), Pia Ragno (342854), Paolo Remondelli (511912), Anna Li Santi (511910), Daniela Alfano (342853), Anna Gorrasi (511909)   +6 more
core   +1 more source

Clinical and pathology features of 170 patients with stage B tumour and 179 with stage C tumour for whom data were available for either central or frontal uPAR^E, uPAR^S or uPAR^PT. Number (percent).

, 2015
Clinical and pathology features of 170 patients with stage B tumour and 179 with stage C tumour for whom data were available for either central or frontal uPARE, uPARS or uPARPT. Number (percent).
Julie Fletcher (562693), Seong Beom Ahn (562691), Mark S. Baker (562698), Sun Young Kwun (562694), Charles Chan (9232), Candice Clarke (562695), Abidali Mohamedali (562692), Pierre H. Chapuis (562697), Owen F. Dent (562696), Edouard C. Nice (233922)   +9 more
core   +1 more source

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer

, 2015
Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma is highly aggressive and mostly metastatic in nature though curable/manageable in part by molecular targeted therapy.
Vine, Kara Lea, Venkatesh, Thejaswini, Indira Chandran, Vineesh,, Ranson, Marie, Lund University., Eppenberger-Castori, Serenella   +5 more
core  

Niche-reprogramming CAR T therapy improves skeletal muscle regeneration and function in preclinical murine models of Duchenne muscular dystrophy. [PDF]

Cell Stem Cell
Afzal H, Rotstein T, Biswas DD, Lin X, Khodabukus A, Luo W, Xu Y, Frair EC, Li Y, Chen J, Kuang S, Flanigan KM, Bursac N, ElMallah MK, Gersbach CA, Diao Y.   +15 more
europepmc   +1 more source

Identification of Urokinase Plasminogen Activator Receptor (uPAR)-Binding Peptides Using Phage Display: Strategy and Downstream Validation. [PDF]

Cancers (Basel)
Sloth AB, Dawoodi IM, Treiberg T, Sinkjaer AW, Andersen IV, Andersen AO, Bøgestad ECS, Rossing M, Stavnsbjerg C, Bakhshinejad B, Kjaer A.   +10 more
europepmc   +1 more source

Macrophage reprogramming by the ultraviolet filter benzophenone-1 promotes malignant phenotypes in breast cancer cells: integrated computational and experimental evidence. [PDF]

Front Mol Biosci
He B, Ding L, Yang X, Zhang T, Ma L.
europepmc   +1 more source

The Translational Value of Preclinical Research: Lessons from More Than Forty Years of Retinal Research. [PDF]

Biomedicines
Bagnoli P.
europepmc   +1 more source

Potential Role of the Urokinase-Type Plasminogen Activator Receptor-Integrin β3 Axis in Podocyte Adhesion Instability and Loss. [PDF]

Kidney Int Rep
Kim JH, Dang BTN, Kim J, Eom M, Cha SK, Kim J.   +5 more
europepmc   +1 more source

Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles. [PDF]

Mol Ther Nucleic Acids
Ramamurthy A, Scimonelli G, Murphy WL, Saha K.   +3 more
europepmc   +1 more source